title: Facilitation of spinal morphine analgesia in normal and morphine tolerant animals by neuropeptide SF and related peptides.
abstract: Neuropeptide FF and related synthetic amidated peptides have been shown to elicit sustained anti-nociceptive responses and potently augment spinal anti-nociceptive actions of spinal morphine in tests of thermal and mechanical nociception. Recent studies have described the occurrence of another octapeptide, neuropeptide SF (NPSF) in the spinal cord and the cerebrospinal fluid and demonstrated its affinity for the NPFF receptors. This study examined the effects of NPSF and two putative precursor peptides, EFW-NPSF and NPAF, on the spinal actions of morphine in normal and opioid tolerant rats using the tailflick and pawpressure tests. In normal rats, NPSF demonstrated weak intrinsic activity but sub-effective doses of the peptide significantly increased the magnitude and duration of spinal morphine anti-nociception in both tests. A low-dose of NPSF also augmented the spinal actions of a delta receptor agonist, deltorphin. The morphine-potentiating effect of NPSF was shared by EFW-NPSF and the octadecapeptide NPAF. In animal rendered tolerant by continuous intrathecal infusion of morphine for 6 days, low dose NPSF itself elicited a significant anti-nociceptive response and potently increased morphine-induced response in both tests. In animals made tolerant by repeated injections of intrathecal morphine, administration of NPSF, EFW-NPSF, and NPAF with morphine reversed the loss of the anti-nociceptive effect and restored the agonist potency. The results demonstrate that in normal animals NPSF and related peptides exert strong potentiating effect on morphine anti-nociception at the spinal level and in tolerant animals these agents can reverse the loss of morphine potency.
authors.affiliation: Department of Pharmacology and Toxicology and Department of Anesthesiology, Faculty of Health Sciences, Queen's University, Kingston, Ont., Canada K7L 3N6. jhamanda@post.queensu.ca
authors.forename: K
authors.initials: K
authors.lastname: Jhamandas
authors.forename: B
authors.initials: B
authors.lastname: Milne
authors.forename: M
authors.initials: M
authors.lastname: Sutak
authors.forename: C
authors.initials: C
authors.lastname: Gouarderes
authors.forename: J-M
authors.initials: JM
authors.lastname: Zajac
authors.forename: H-Y T
authors.initials: HY
authors.lastname: Yang
mesh_terms: D000698:Analgesia; D000818:Animals; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004361:Drug Tolerance / Q000502:physiology*; D008297:Male; D009020:Morphine / Q000494:pharmacology; D009479:Neuropeptides / Q000494:pharmacology*; D009842:Oligopeptides / Q000494:pharmacology; D010147:Pain Measurement; D010455:Peptides / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013116:Spinal Cord / Q000187:drug effects*
chemical_list: D009479:Neuropeptides; D009842:Oligopeptides; D010455:Peptides; C511785:glutamyl-phenylalanyl-tryptophyl-seryl-leucyl-alanyl-alanyl-prolyl-glutaminyl-arginyl-phenylalaninamide; C414382:neuropeptide SF; C059567:deltorphin; D009020:Morphine; C061209:A18Famide